Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Mapi Pharma Ltd.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07185815CT.gov Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | — | Recruiting | — | — | — |
NCT06589817CT.gov A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia | — | Not Yet Recruiting | — | — | — |
NCT05368558CT.gov Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia | — | Terminated | — | — | — |
NCT05168007CT.gov Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia | — | Unknown | — | — | — |
NCT04578756CT.gov Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder | — | Completed | — | — | — |
NCT03817502CT.gov Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | — | Recruiting | — | — | — |
NCT03593213CT.gov Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia | — | Terminated | — | — | — |
NCT01626872CT.gov Long-Term Study of MP-214 in Patients With Schizophrenia | — | Completed | — | — | — |
NCT01625897CT.gov A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia | — | Completed | — | — | — |
NCT01625000CT.gov Safety and Efficacy of MP-214 in Patients With Schizophrenia | — | Completed | — | — | — |
Show 11 more trialsShow fewer
NCT01626859CT.gov A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia | — | Completed | — | — | — |
NCT01626885CT.gov A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia | — | Completed | — | — | — |
NCT01412060CT.gov A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia | — | Completed | — | — | — |
NCT01376076CT.gov Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia | — | Completed | — | — | — |
NCT01104792CT.gov Long-term Study of Cariprazine in Patients With Schizophrenia | — | Completed | — | — | — |
NCT01104779CT.gov Safety and Efficacy of Cariprazine in Schizophrenia | — | Completed | — | — | — |
NCT01104766CT.gov Safety and Efficacy of Cariprazine in Patients With Schizophrenia | — | Completed | — | — | — |
NCT00839852CT.gov A Study of Cariprazine in Patients With Chronic Stable Schizophrenia | — | Completed | — | — | — |
NCT00694707CT.gov Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia | — | Completed | — | — | — |
NCT00862992CT.gov Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia | — | Completed | — | — | — |
NCT00404573CT.gov Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Schizophrenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cariprazine (this asset) | Mapi Pharma Ltd. | P3 | BB · 70 |
| Trospium | European Group for Research In Schizophrenia | P4 | BBB |
| Xanomeline | European Group for Research In Schizophrenia | P4 | BBB |
| Asenapine | Noven Pharmaceuticals, Inc. | P4 | BBB |
| Lurasidone | Aziende Chimiche Riunite Angelini Francesco S.p.A | P4 | BBB |
| Brexpiprazole | Humanis Saglık Anonim Sirketi | P4 | BBB |
| Bitopertin | Hoffmann-La Roche | P3 | BBB |
| Raloxifene | Shanghai Mental Health Center | P4 | BBB |
| Pyridoxol | Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara | P4 | BBB |
+42 more in the Schizophrenia cohort
Other indications for Cariprazine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar I Disorder | — | P4 | BBB · 73 |
| Major Depressive Disorder | — | P4 | BB · 69 |
| Depressive Disorder | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cariprazine in Schizophrenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cariprazine-schizophrenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →